Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on December 9, 2021, regarding events occurring on December 6, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. Note: The request metadata referenced "Serina Therapeutics," but the filing text explicitly identifies the registrant as AgeX Therapeutics, Inc.
Key Financial Metrics and Debt
- Debt Financing: On December 6, 2021, the company borrowed an additional $1.0 million under its 2019 Loan Agreement with Juvenescence Limited.
- Total Facility Utilization: The company has now borrowed the full $7.0 million available under the 2019 Loan Agreement.
- Repayment Terms: The outstanding principal balance of $7.0 million is due and payable on February 14, 2022.
- Additional Liquidity: The company retains $500,000 of available credit under a separate Secured Convertible Facility Agreement entered into in March 2020, subject to lender approval.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, cash flow, or margins.
Material Changes
The primary material change reported is the full utilization of the $7.0 million credit facility under the 2019 Loan Agreement. This action increases the company's immediate debt obligations, with the entire principal balance becoming due in approximately two months (February 14, 2022).
Outlook, Risks, and Contingencies
- Default Risks: The lender (Juvenescence) may declare the loan immediately due and payable if an Event of Default occurs. Defined events include failure to pay within 10 business days, failure to perform obligations, insolvency, or a material adverse change in financial condition.
- Cross-Default Provisions: Default triggers include other indebtedness exceeding $100,000 becoming due early or indebtedness exceeding $25,000 not being paid when due.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements, noting that actual results may differ materially from anticipated results due to various risk factors.
Investor Verification Checklist
- Verify the company's ability to repay the $7.0 million principal balance by the February 14, 2022, maturity date.
- Confirm the status of the $500,000 remaining credit line under the March 2020 Secured Convertible Facility Agreement.
- Review recent periodic reports for updated "Risk Factors" regarding liquidity and solvency.
- Monitor for any announcements regarding refinancing or extension of the 2019 Loan Agreement prior to the repayment date.